Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...
Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO
The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...
GlobalData on MSN2d
Takeda announces appointment of Julie Kim as CEO
Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
FierceBiotech3d
Takeda axes failed epilepsy asset after FDA weighs in on data package
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...
Takeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy Rating
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...